A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney...

Area of Science:

• Nephrology
• Endocrinology
• Transplantation

Background:

• Hyperglycemia post-kidney transplant increases risks.
• Posttransplantation Diabetes Mellitus (PTDM) is a concern in non-diabetic recipients.
• Previous trials showed exogenous insulin reduces PTDM odds.

Purpose of the Study:

• To test if insulin pump therapy (CSII) improves glycemic control versus basal insulin and standard care.
• To assess the efficacy and safety of CSII for PTDM prevention in kidney transplant recipients.
• To present an algorithm for CSII in this patient population.

Main Methods:

• Multi-center, randomized, controlled trial.
• Three arms: CSII, once-daily insulin isophane, and standard-of-care.
• CSII used insulin lispro with a specific afternoon-focused dosing algorithm.

Main Results:

• CSII group showed superior fasting and post-supper glucose control in the first post-operative week.
• Mild hypoglycemia occurred in 2/24 CSII patients.
• CSII demonstrated similar safety and superior short-term efficacy compared to other groups.

Conclusions:

• CSII is a safe and effective option for managing hyperglycemia post-kidney transplant.
• The developed CSII algorithm shows promise for PTDM prevention.
• Further research may explore long-term outcomes of CSII in transplant patients.